[go: up one dir, main page]

WO2013013017A3 - Compositions et procédés pour modifier la glycosylation de substances thérapeutiques pour les troubles du stockage lysosomal - Google Patents

Compositions et procédés pour modifier la glycosylation de substances thérapeutiques pour les troubles du stockage lysosomal Download PDF

Info

Publication number
WO2013013017A3
WO2013013017A3 PCT/US2012/047354 US2012047354W WO2013013017A3 WO 2013013017 A3 WO2013013017 A3 WO 2013013017A3 US 2012047354 W US2012047354 W US 2012047354W WO 2013013017 A3 WO2013013017 A3 WO 2013013017A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
modifying
compositions
glycosylation
lysosomal storage
Prior art date
Application number
PCT/US2012/047354
Other languages
English (en)
Other versions
WO2013013017A2 (fr
Inventor
Anthony Rossomando
Brian Bettencourt
Original Assignee
Alnylam Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals, Inc. filed Critical Alnylam Pharmaceuticals, Inc.
Publication of WO2013013017A2 publication Critical patent/WO2013013017A2/fr
Publication of WO2013013017A3 publication Critical patent/WO2013013017A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne de manière générale des compositions et des procédés de production de protéines lysosomales qui présentent une structure glycane modifiée, de telle sorte que la protéine peut être délivrée efficacement dans les lysosomes de cellules cibles (par exemple par endocytose médiée par le mannose-6-phosphate). Les protéines lysosomales sont produites en modifiant les voies de glycosylation et/ou le ciblage lysosomal dans une cellule hôte en utilisant une molécule effectrice d'ARN, comme un ARNsi. Les protéines lysosomales à glycane modifié produites au moyen des procédés décrits ici présentent des propriétés améliorées.
PCT/US2012/047354 2011-07-21 2012-07-19 Compositions et procédés pour modifier la glycosylation de substances thérapeutiques pour les troubles du stockage lysosomal WO2013013017A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161510437P 2011-07-21 2011-07-21
US61/510,437 2011-07-21
US201161532999P 2011-09-09 2011-09-09
US61/532,999 2011-09-09
US201261617322P 2012-03-29 2012-03-29
US61/617,322 2012-03-29

Publications (2)

Publication Number Publication Date
WO2013013017A2 WO2013013017A2 (fr) 2013-01-24
WO2013013017A3 true WO2013013017A3 (fr) 2013-04-18

Family

ID=47558721

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/047354 WO2013013017A2 (fr) 2011-07-21 2012-07-19 Compositions et procédés pour modifier la glycosylation de substances thérapeutiques pour les troubles du stockage lysosomal

Country Status (1)

Country Link
WO (1) WO2013013017A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014145519A2 (fr) * 2013-03-15 2014-09-18 Viropharma Holdings Limited Compositions de c1.inh et méthodes pour la prévention et le traitement de troubles associés à un déficit en inhibiteur de c1 estérase
WO2015054569A1 (fr) * 2013-10-10 2015-04-16 Viropharma Holdings Limited Procédés d'inhibition de la voie alternative d'activation du système immunitaire complémentaire et compositions utilisées dans ces procédés
WO2015095568A1 (fr) 2013-12-18 2015-06-25 Kelvin Lee Réduction de l'activité d'une lipase dans des formulations de produits
LT4273241T (lt) 2014-09-30 2025-02-10 Amicus Therapeutics, Inc. Labai stipriai veikianti rūgštinė alfa-gliukosidazė, pasižyminti didesniu angliavandenių kiekiu
TWI760296B (zh) * 2014-09-30 2022-04-11 美商阿米庫斯醫療股份有限公司 高效經修飾之酸性α-葡萄糖苷酶及其製造與使用方法
WO2017029148A1 (fr) * 2015-08-14 2017-02-23 Cancer Research Technology Limited Agents de liaison du facteur de croissance 2 analogue à l'insuline (igf 2)
NZ743230A (en) 2015-12-30 2025-06-27 Amicus Therapeutics Inc Augmented acid alpha-glucosidase for the treatment of pompe disease
KR102618519B1 (ko) 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
US10227577B2 (en) 2016-03-30 2019-03-12 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
PL3436053T3 (pl) * 2016-03-30 2022-08-01 Amicus Therapeutics, Inc. Formulacje zawierające rekombinowaną kwaśną alfa-glukozydazę
EP3293203A1 (fr) * 2016-09-12 2018-03-14 Genethon Variants d'alpha-glucosidase acide et leurs utilisations
US11339406B2 (en) 2016-09-12 2022-05-24 Genethon Acid-alpha glucosidase variants and uses thereof
JP2019535839A (ja) 2016-11-29 2019-12-12 ピュアテック ヘルス エルエルシー 治療剤の送達のためのエクソソーム
KR20250044950A (ko) 2017-05-15 2025-04-01 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 인간 산 알파-글루코시다제

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US20060188975A1 (en) * 2003-08-21 2006-08-24 Mani Ramaswami Genetically modified somatic cells for sustained secretion of lysosomal proenzymes deficient in lysosomal storage disorders
WO2011005786A2 (fr) * 2009-07-06 2011-01-13 Alnylam Pharmaceuticals, Inc. Compositions et procédés pour améliorer la production d'un produit biologique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US20060188975A1 (en) * 2003-08-21 2006-08-24 Mani Ramaswami Genetically modified somatic cells for sustained secretion of lysosomal proenzymes deficient in lysosomal storage disorders
WO2011005786A2 (fr) * 2009-07-06 2011-01-13 Alnylam Pharmaceuticals, Inc. Compositions et procédés pour améliorer la production d'un produit biologique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FREEZE, H.: "Towards a therapy for phosphomannomutase 2 defeciency, the defect in CDG-la patients.", BIOCHIM BIOPHYS ACTA, vol. 1792, no. 9, September 2009 (2009-09-01), pages 835 - 840 *

Also Published As

Publication number Publication date
WO2013013017A2 (fr) 2013-01-24

Similar Documents

Publication Publication Date Title
WO2013013017A3 (fr) Compositions et procédés pour modifier la glycosylation de substances thérapeutiques pour les troubles du stockage lysosomal
WO2013013013A3 (fr) Compositions et procédés de production de glycoprotéines modifiées
EP4253395A3 (fr) Procédés de préparation d'agents arn conjugués à des carbohydrates
WO2012135805A3 (fr) Administration et formulation d'acides nucléiques génétiquement modifiés
WO2012153193A3 (fr) Conjugués protéine-principe actif et leur procédé de préparation
WO2014186585A3 (fr) Procédés et compositions pour le traitement d'une maladie génétique
WO2012101206A3 (fr) Nouvelles glycosides hydrolases de champignons thermophiles
WO2012170889A8 (fr) Lipides clivables
WO2013057141A3 (fr) Variants d'alpha-amylase et polynucléotides les codant
WO2011082425A3 (fr) Variants d'alpha-amylase et polynucleotides les codant
WO2013019827A3 (fr) Polypeptides ayant une activité xylanase et polynucléotides codant pour ceux-ci
EP4253534A3 (fr) Variants d'alpha-amylase et polynucléotides les codant
HK1198170A1 (en) Pseudomonas exotoxin a with less immunogenic b cell epitopes
EP3805348A3 (fr) Polypeptides avant une activite d activation cellulolytique et polynucleotides codant pour ceux-ci
IN2014CN02100A (fr)
EP4241854A3 (fr) Enzyme des maladies lysosomales
WO2014097113A3 (fr) Production de protéines thérapeutiques dans des cellules de mammifère génétiquement modifiées
WO2012136898A3 (fr) Nouvelles cutinases, leur préparation et leurs utilisations
WO2013188305A3 (fr) Variants de la beta-xylosidase fongique
WO2011115810A3 (fr) Arni spécifique d'une isoforme basé sur une redondance ou une dégénérescence de codons
IN2015DN03206A (fr)
WO2013058482A3 (fr) Médicament anticancéreux à base d'acide nucléique multifonctionnel apte à cibler et de traiter, procédé de préparation de celui-ci et composition anticancéreuse le comprenant
MX346117B (es) Metodo para produccion mejorada de proteinas en hongo filamentoso.
WO2010120874A3 (fr) Agents thérapeutiques chimériques, compositions, et leurs procédés d'utilisation
WO2011151512A3 (fr) Procédé de production de protéines à partir de champignons filamenteux

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12815544

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12815544

Country of ref document: EP

Kind code of ref document: A2